Physician profile
Alan Roy Shain
NPI 1316945306
$4,806.05
in general payments reported to CMS, 2019-2025
33 companies · $41.63 in 2025
The $41.63 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,279 · 2020: $1,142 · 2021: $2,298 · 2022: $45.25 · 2025: $41.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $41.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $41.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $608.32 | 2019-2021 | |
| Novo Nordisk INC | $503.20 | 2019-2021 | |
| Allergan, INC. | $478.81 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $471.52 | 2019-2021 | |
| Pfizer INC. | $422.67 | 2019-2021 | |
| Abbvie INC. | $401.62 | 2021-2022 | |
| Lilly USA, LLC | $380.77 | 2019-2021 | |
| Glaxosmithkline, LLC. | $196.03 | 2019-2025 | Bexsero |
| Daiichi Sankyo INC. | $172.06 | 2019-2021 | |
| Amarin Pharma, INC. | $170.62 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $147.07 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.39 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.44 | 2019-2021 | |
| Antares Pharma, INC. | $92.86 | 2021 | |
| Eisai INC. | $77.06 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $67.71 | 2019-2021 | |
| Sanofi Pasteur INC. | $56.47 | 2019-2021 | |
| Astellas Pharma US INC | $52.52 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $51.23 | 2020-2021 | |
| Mylan Specialty L.P. | $43.71 | 2019-2020 | |
| Alkermes, INC. | $26.41 | 2025 | Vivitrol |
| Novartis Pharmaceuticals Corporation | $16.40 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.84 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.49 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.53 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.19 | 2019 | |
| Tandem Diabetes Care, INC. | $12.90 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.76 | 2020 | |
| Amgen INC. | $12.49 | 2019 | |
| Merck Sharp & Dohme LLC | $12.11 | 2019 | |
| Snap Diagnostics LLC | $11.86 | 2021 | |
| Zyla Life Sciences, INC. | $11.53 | 2019 | |
| Horizon Therapeutics Plc | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Shain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.